Company news
Boundless Bio, Inc. (NASDAQ:BOLD) news
Boundless Bio, Inc. news releases on 6ix. Latest, Jun 23, 2026: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private…
Press releases & updates
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
June 22, 2026
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
May 8, 2026
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
April 17, 2026
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
March 16, 2026
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 8, 2026
Boundless Bio to Participate in the Leerink Global Healthcare Conference
March 4, 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
January 20, 2026
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
November 5, 2025
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
August 5, 2025
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 5, 2025
Boundless Bio Announces Portfolio Prioritization and Runway Extension
May 23, 2025
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
May 9, 2025
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
April 3, 2025
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
March 27, 2025
Boundless Bio to Participate in the Leerink Global Healthcare Conference
February 26, 2025
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
February 2, 2025
Boundless Bio Announces Pipeline and Leadership Updates
December 11, 2024
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
November 6, 2024
Boundless Bio Announces Departure of Chief Financial Officer
October 13, 2024
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
August 11, 2024
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
May 12, 2024
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
April 10, 2024
Boundless Bio Announces Pricing of Initial Public Offering
March 26, 2024